Vanguard Fiduciary Trust
BDTX icon

Vanguard Fiduciary Trust’s Black Diamond Therapeutics BDTX Stock Holding History

Vanguard Fiduciary Trust’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$573K Buy
309,853
+49,945
+19% +$122K ﹤0.01% 3230
2026
Q1 		$554K Buy
+259,908
New +$618K ﹤0.01% 3180

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return

Vanguard Fiduciary Trust's BDTX Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Black Diamond Therapeutics (BDTX) stake by 19% in Q2 2026, buying an estimated $122K and bringing the position to 309,853 shares worth $573K. The position accounts for ﹤0.01% of the portfolio, ranked #3230.

Vanguard Fiduciary Trust first reported a position in BDTX in Q1 2026 and has held it in 2 quarters since. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Vanguard Fiduciary Trust held 309,853 shares of Black Diamond Therapeutics worth $573K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 49,945 Black Diamond Therapeutics shares in Q2 2026, an estimated $122K.
  • Black Diamond Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3230 holding.
  • Vanguard Fiduciary Trust first reported a position in Black Diamond Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.